3002 – REPROGRAMMING OF SERINE METABOLISM IS A METABOLIC VULNERABILITY IN FMS-LIKE TYROSINE KINASE 3 (FLT3) MUTANT ACUTE MYELOID LEUKAEMIA
Sign Up to like & getrecommendations! Published in 2020 at "Experimental Hematology"
DOI: 10.1016/j.exphem.2020.09.024
Abstract: Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene occur in approximately 30% of all acute myeloid leukaemias (AMLs) and are associated with poor prognosis. The clinical utility of FLT3 inhibitor monotherapy has been limited… read more here.
Keywords: synthesis; flt3 mutant; flt3; aml ... See more keywords
C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-22-0411
Abstract: While transcription factor C/AAT-enhancer binding protein a (C/EBPa) is critical for normal and leukemic differentiation, its role on cell and metabolic homeostasis is largely unknown in cancer. Here, multi-omics analyses uncovered a coordinated activation of… read more here.
Keywords: flt3; lipid oxidative; oxidative stress; fatty acid ... See more keywords
Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-124178
Abstract: Targeted inhibitors to oncogenic kinases demonstrate encouraging clinical responses early in the treatment course, however, most patients will relapse due to target-dependent mechanisms that mitigate enzyme-inhibitor binding or through target-independent mechanisms, such as alternate activation… read more here.
Keywords: response; flt3; adaptive resistance; resistance ... See more keywords
Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3-mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Haematologica"
DOI: 10.3324/haematol.2022.281456
Abstract: Chimeric antigen receptor (CAR) T-cell immunotherapies targeting CD19 or CD22 induce remissions in the majority of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), although relapse due to target antigen loss or downregulation has emerged… read more here.
Keywords: flt3; cell; kmt2a rearranged; aml ... See more keywords